Skip to main content
Black Health logo Black Health

Weight management / GLP-1 review

Henry Meds review for Black patients (2026)

3.9/5

Henry Meds is competitive with Hims Weight Loss on price and medication menu, but operationally trails the public-company incumbents on reliability and customer-service consistency.

Last reviewed How we review

Pros and cons

Pros

  • Same compounded-semaglutide access as Hims Weight Loss at a comparable price point.
  • Tirzepatide compounded option available in addition to semaglutide; broader menu than Hims.
  • No annual contract; subscription is month-to-month and pausable.
  • Faster intake than most competitors; many patients receive first shipment within 5-7 days.

Cons

  • Same FDA compounded-GLP-1 regulatory exposure as Hims Weight Loss; future of compounded semaglutide is uncertain in 2026-2027.
  • Operational scale is smaller than Hims & Hers; customer-service consistency has been mixed per public reviews.
  • Side-effect management is asynchronous messaging only; no live clinician channel.
  • No behavior-change coaching included; medication-only.
  • No Black-clinician filter at intake.

Pricing and coverage

Pricing
Compounded semaglutide from $249/month; tirzepatide from $399/month. Self-pay only.
Insurance
No commercial insurance
Notes
Self-pay only. HSA / FSA eligible. No commercial or Medicaid insurance accepted. Compounded GLP-1 is not insurance-reimbursed anywhere in the US as of 2026.

How Henry Meds compares

Henry Meds is one of several compounded-GLP-1 telehealth services that emerged during the 2022-2024 semaglutide shortage. It is structurally similar to Hims Weight Loss: monthly subscription, compounded semaglutide or tirzepatide, no insurance. The differences are operational reliability (Hims is a public company; Henry is smaller) and menu breadth (Henry adds compounded tirzepatide).

The regulatory caveat

Compounded semaglutide is under active FDA enforcement scrutiny. FDA declared the semaglutide shortage resolved in October 2024, which technically removed the legal basis for routine compounding. Enforcement has been gradual but the trend is toward narrower compounded access. Tirzepatide is still on the FDA shortage list as of 2026 so its compounded path is less exposed; semaglutide is more exposed.

This applies to every compounded-GLP-1 provider, not just Henry Meds. Plan for the possibility you may need to transition to branded Wegovy / Zepbound or off medication entirely in the next 12-18 months.

Who picks Henry over Hims

If you want tirzepatide rather than semaglutide, Henry's compounded tirzepatide menu is the meaningful differentiator. If you want semaglutide only and operational reliability is your priority, Hims Weight Loss is the better default. The $50 monthly price difference is real but the customer-service and shipping consistency premium at Hims is also real.

Our methodology

Evaluated against Hims Weight Loss, Found, Calibrate, and Form Health on cost, medication menu, operational reliability, and behavior-change support. October 2026.

Was this helpful?

Your feedback shapes what we cover next.

Thanks for letting us know.

If you found this useful, sign up for our newsletter to get more like this.

Thanks. What was missing?

Optional. We read every response.

Thanks.

We use this to prioritize the next round of edits.